Browse > Article
http://dx.doi.org/10.3904/kjim.2010.25.4.364

Increased Expression of Cyclooxygenase-2 is Associated with the Progression to Cirrhosis  

Jeong, Soung-Won (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Jang, Jae-Young (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Lee, Sae-Hwan (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Kim, Sang-Gyun (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Cheon, Young-Koog (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Kim, Young-Seok (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Cho, Young-Deok (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Kim, Hong-Soo (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Lee, Joon-Seong (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Jin, So-Young (Department of Pathology, Soonchunhyang University College of Medicine)
Shim, Chan-Sup (Department of Internal Medicine, Konkuk University School of Medicine)
Kim, Boo-Sung (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.25, no.4, 2010 , pp. 364-371 More about this Journal
Abstract
Background/Aims: To investigate the degree of cyclooxygenase-2 (COX-2) protein expression in chronic hepatitis and cirrhosis. Methods: COX-2 protein expression was evaluated in 43 cases of chronic hepatitis and 24 cases of cirrhosis using immunohistochemical techniques. The COX-2 immunohistochemical staining score was assessed using the scoring systems of Pazirandeh et al and Qiu et al. and each scoring system was based on a sum of the parameters of staining intensity and distribution. Results: The mean COX-2 expression scores in chronic hepatitis and cirrhosis were $2.5{\pm}1.3$ vs. $3.3{\pm}1.1$ (p = 0.008), and $3.2{\pm}2.0$ vs. $4.5{\pm}1.7$ (p = 0.006), respectively, based on the Pazirandeh et al. and Qiu et al. scoring systems. The percentage samples of high COX-2 expression score (4 to 5) in chronic hepatitis and cirrhosis were 16.3% vs. 45.8% (p = 0.022), and 23.3% vs. 50% (p = 0.021), respectively, based on the two scoring systems. The mean COX-2 expression scores based on the severity of hepatic fibrosis scored using Ishak's modified staging system (fibrosis score 0 to 3 vs. 4 to 6) were $2.4{\pm}1.3$ vs. $3.2{\pm}1.1$ (p = 0.009), and $3.1{\pm}2.0$ vs. $4.3{\pm}1.8$ (p = 0.009), respectively, based on the two scoring systems. Conclusions: COX-2 expression was significantly higher in liver cirrhosis group than in chronic hepatitis. COX-2 expression scores according to Ishak's staging was significantly higher in the advanced fibrosis group. COX-2 may play a role in the progression of hepatic fibrosis.
Keywords
Cyclooxygenase 2; Immunohistochemistry; Hepatitis; chronic; Liver cirrhosis;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Denda A, Endoh T, Kitayama W, et al. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis 1997;18:1921-1930.   DOI   ScienceOn
2 Cheng AS, Chan HL, Leung NW, et al. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of antiviral therapy. Aliment Pharmacol Ther 2002;16:251-260.   DOI   ScienceOn
3 Pazirandeh S, Khettry U, Gordon FD, Resnick RH, Murray JE, Sheth SG. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci 2007;52:220-227.   DOI   ScienceOn
4 Planagumà A, Clària J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J 2005;19:1120-1122.   DOI
5 Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.   DOI   ScienceOn
6 Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002;8:815-817.   DOI
7 Morinaga S, Yamamoto Y, Noguchi Y, et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:1110-1116.   DOI   ScienceOn
8 Yu J, Hui AY, Chu ES, et al. Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. Gut 2007;56:991-999.   DOI   ScienceOn
9 Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004;96:1734-1735.   DOI   ScienceOn
10 Mallat A, Gallois C, Tao J, et al. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem 1998;273:27300-27305.   DOI   ScienceOn
11 Failli P, DeFranco RM, Caligiuri A, et al. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 2000;119:479-492.   DOI   ScienceOn
12 Hui AY, Leung WK, Chan HL, et al. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 2006;26:125-136.   DOI   ScienceOn
13 Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-1628.   DOI   ScienceOn
14 Yu J, Wu CW, Chu ES, et al. Elucidation of the role of ${COX-}_2$ in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 2008;372:571-577.   DOI   ScienceOn
15 Yamamoto H, Kondo M, Nakamori S, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology 2003;125:556-571.   DOI   ScienceOn
16 Tu CT, Guo JS, Wang M, Wang JY. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. J Gastroenterol Hepatol 2007;22:877-884.   DOI   ScienceOn
17 Radaeva S, Li Y, Hacker HJ, Burger V, Kopp-Schneider A, Bannasch P. Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J Hepatol 2000;33:580-600.   DOI   ScienceOn
18 Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995;21:620-626.
19 Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990;50:3400-3407.
20 Ueno Y, Moriyama M, Uchida T, Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 2001;33:357-362.   DOI   ScienceOn
21 Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002;139:234-243.   DOI   ScienceOn
22 Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and ${COX-}_2$ in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of ${COX-}_2$. Mod Pathol 2004;17:1169-1179.   DOI   ScienceOn
23 Gallois C, Habib A, Tao J, et al. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factoralpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem 1998;273:23183-23190.   DOI   ScienceOn
24 Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.   DOI   ScienceOn
25 Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696.   DOI   ScienceOn
26 Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 $({COX-}_2)$ mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999;90:1338-1343.   DOI
27 Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008;62:444-449.   DOI   ScienceOn
28 Kondo M, Yamamoto H, Nagano H, et al. Increased expression of ${COX-}_2$ in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-4012.
29 Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412.
30 Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase- 2 $({COX-}_2)$ in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a ${COX-}_2$ inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418.
31 Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
32 Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916.   DOI
33 Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789.
34 Dimberg J, Samuelsson A, Hugander A, Söderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999;45:730-732.   DOI   ScienceOn
35 Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-525.